NCT00182767View on ClinicalTrials.gov

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

April 30, 2012

Study Completion Date

May 31, 2014

Conditions
Fallopian Tube CancerFemale Reproductive CancerRecurrent Breast CancerRecurrent Ovarian Epithelial CancerStage III Ovarian Epithelial CancerStage IV Breast CancerStage IV Ovarian Epithelial Cancer
Interventions
DRUG

ixabepilone

Given IV

DRUG

pegylated liposomal doxorubicin hydrochloride

Given IV

Trial Locations (5)

10065

Weill Medical College of Cornell University, New York

10461

Albert Einstein College of Medicine, The Bronx

12208

Women's Cancer Care Associates LLC, Albany

06030

University of Connecticut, Farmington

10467-2490

Montefiore Medical Center - Moses Campus, The Bronx

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00182767 - Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer | Biotech Hunter | Biotech Hunter